Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.33 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.33 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28055241 | 0.89 | DPP4 (0.37) | AAK1DPP4APPSLC7A5 | |
| SCHEMBL11221171 | 0.89 | DPP4 (0.37) | AAK1DPP4APPSLC7A5 | |
| SCHEMBL6246072 | 0.80 | CYP2C19 (0.39) | AAK1 | |
| SCHEMBL17513198 | 0.76 | FFAR1 (0.41) | AAK1APP | |
| SCHEMBL3453796 | 0.73 | DPP4 (0.37) | AAK1DPP4APPSLC7A5 | |
| SCHEMBL27773550 | 0.73 | GABBR2 (0.42) | AAK1DPP4SLC7A5 | |
| SCHEMBL6032240 | 0.73 | DPP4 (0.39) | AAK1DPP4SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL24187349 | 0.70 | DPP4 (0.43) | AAK1DPP4SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL31618904 | 0.70 | DPP4 (0.43) | AAK1DPP4SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL29943608 | 0.70 | TDP1 (0.44) | AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7101871-B2 | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK & CO., INC. (US) | 2006-09-05 | — | — | US | disclosed |
| US-20040254167-A1 | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME CORP. | 2004-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254167-A1 | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | DPP4, DPP3, DPP7 | AAK1 2261/4885DPP4 1/4885SLC1A3 702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.